Portola reversal agent for Xarelto succeeds in late stage trial

ORLANDO, Fla., Nov 11 (Reuters) - A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective in a late stage study, according to data presented on Wednesday that should help make the case for its approval.